Varicella-zoster virus (VZV) immunoglobulin G (IgG) antibody IVD, kit, enzyme immunoassay (EIA)

Varicella-zoster virus (VZV) IgG antibody IVD kits use enzyme immunoassay (EIA) to detect antibodies in patient samples, helping diagnose past exposure to chickenpox or shingles. Clinically, these tests aid in assessing immunity status, particularly for high-risk individuals like pregnant women, immunocompromised patients, or healthcare workers. Results guide vaccination decisions or infection control measures by confirming prior infection. The kits are designed for laboratory use, providing objective, standardized testing for VZV IgG presence.

These diagnostic kits are typically regulated as in vitro diagnostic (IVD) devices, with classification and supply requirements varying by jurisdiction. They are sold as complete test systems, including reagents, controls, and instructions, and are intended for professional use only. Compliance with IVD-specific standards ensures accuracy and reliability for clinical decision-making. Availability may depend on local health authority approvals and market-specific labeling.